Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Ottawa
$120,000.00
Characterizing the effect of a clinically approved compound on colorectal cancer stem cell functions
EF 2025-26
Résumé
Colorectal cancer is the third most common cause of cancer deaths in Canada. While colorectal cancer diagnosis is prevailing in older patients, more and more young people (20-49 y/o) get diagnosed with early-onset disease. Thankfully, many diagnostic and treatment advances have significantly improved survival rates. Still, many patients continue to experience treatment resistance, disease relapse, and metastasis. The root cause of these issues lies in the existence of cancer stem cells. These cells are significantly more resistant to treatment than most of the cells that constitute a tumor, so they often remain in the patient's body even after cycles of chemotherapy. Cancer stem cells also possess a unique ability to restart tumor growth. While many researchers began to develop anti-cancer stem cell drugs, the roadblock to discovering such medicines was their toxicity towards normal stem cells, which are crucial for the regeneration of our tissues, such as the intestinal lining and skin. In this research proposal, we aim to identify a new drug and molecular targets that will enable us to kill cancer stem cells in colorectal cancer while leaving normal tissues unaffected. We screened >1500 clinically approved molecules to find and further develop those that selectively stop the initiation of tumors and identified a hit candidate. In our laboratory, we use patient-derived organoids, which are mini-tumors grown in culture dishes from cancerous tissues of patients who consented to donate them after surgery. We will test these drugs in patient-derived tumor and healthy tissue organoids and thoroughly study their mechanism of action. We hope to discover new mechanisms to which colorectal cancer stem cells are addicted, enabling us to develop more efficacious and safe treatments that improve survival and decrease recurrence of colorectal cancer.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559069
Name
Yevdokimova Veronika
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Characterizing the effect of a clinically approved compound on colorectal cancer stem cell functions
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cancer Stem Cells; Colorectal Cancer; Patient-Derived Organoids; Phenotypic Screening; Yb1
Abstract
Colorectal cancer is the third most common cause of cancer deaths in Canada. While colorectal cancer diagnosis is prevailing in older patients, more and more young people (20-49 y/o) get diagnosed with early-onset disease. Thankfully, many diagnostic and treatment advances have significantly improved survival rates. Still, many patients continue to experience treatment resistance, disease relapse, and metastasis. The root cause of these issues lies in the existence of cancer stem cells. These cells are significantly more resistant to treatment than most of the cells that constitute a tumor, so they often remain in the patient's body even after cycles of chemotherapy. Cancer stem cells also possess a unique ability to restart tumor growth. While many researchers began to develop anti-cancer stem cell drugs, the roadblock to discovering such medicines was their toxicity towards normal stem cells, which are crucial for the regeneration of our tissues, such as the intestinal lining and skin. In this research proposal, we aim to identify a new drug and molecular targets that will enable us to kill cancer stem cells in colorectal cancer while leaving normal tissues unaffected. We screened >1500 clinically approved molecules to find and further develop those that selectively stop the initiation of tumors and identified a hit candidate. In our laboratory, we use patient-derived organoids, which are mini-tumors grown in culture dishes from cancerous tissues of patients who consented to donate them after surgery. We will test these drugs in patient-derived tumor and healthy tissue organoids and thoroughly study their mechanism of action. We hope to discover new mechanisms to which colorectal cancer stem cells are addicted, enabling us to develop more efficacious and safe treatments that improve survival and decrease recurrence of colorectal cancer.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Yevdokimova, Veronika
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~